← brief for 2026-08-27 · Slowing decline

Renal Effects of Glucagon-like Peptide-1 Receptor Agonists in Diabetic Kidney Disease: A Narrative Review of Mechanisms and Clinical Evidence.

Article No results yet Peer reviewed

Key takeaways

A review of GLP-1 drugs, the same family as Ozempic, for kidney disease caused by diabetes. It summarizes how these drugs act on blood sugar, weight, blood pressure, cholesterol, and inflammation, and why that might protect kidneys on top of standard treatment. This is a summary of other people's work with no new results, so treat it as background reading rather than evidence.

Who did this work

Braha A · Timar B · Sturza A · Timar R

Source

Article · PubMed, CKD nutrition RCTs · 2026 Aug 5
https://pubmed.ncbi.nlm.nih.gov/42654406/